45
Participants
Start Date
February 6, 2017
Primary Completion Date
October 31, 2022
Study Completion Date
October 31, 2022
CWP232291
"For cohort 1-3, a fixed dose of ara-C at 1 G/m2 will be administered IV over 2 hours daily from Day 1 to Day 5 following CWP232291 infusion.~For cohort 4, a fixed dose of ara-C at 1 G/m2 will be administered IV over 2 hours daily from Day 1 to Day 7 following 250 mg/m2 CWP232291 infusion."
The University of Texas MD Anderson Cancer Center, Houston
University of Washington, Seattle
Samsung medical center, Seoul
Seoul National University Hospital, Seoul
Asan Medical Center, Seoul
Lead Sponsor
JW Pharmaceutical
INDUSTRY